A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)

Annals of Pharmacotherapy

Volumn 48, Issue 2, 2014, Pages 209-225

  Sharma, Alok ^a   Couture, Justin ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

ADHD; amphetamine; atomoxetine; attention deficit hyperactivity disorder; bupropion; clonidine; dopamine; etiology; guanfacine; methylphenidate; norepinephrine; pathophysiology; prefrontal cortex; treatment; treatment guidelines; tricyclic antidepressants

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; A 412997; AMANTADINE; AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE PLUS DEXAMPHETAMINE; ATOMOXETINE; CARBIDOPA PLUS LEVODOPA; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOPAMINE; DOPAMINE RECEPTOR AFFECTING AGENT; GUANFACINE; IMIPRAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NORADRENALIN; NORTRIPTYLINE; PIRIBEDIL; PROCENTRA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL DREAMING; ACADEMIC ACHIEVEMENT; AKINESIA; ANOREXIA; ATAXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLURRED VISION; BRADYCARDIA; BRADYKINESIA; CEREBROVASCULAR ACCIDENT; CONFUSION; CONSTIPATION; DELUSION; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSMENORRHEA; DYSURIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEART BLOCK; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HEARTBURN; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; IMPOTENCE; IMPULSIVENESS; INSOMNIA; LETHARGY; LIVER TOXICITY; MANIA; MIGRAINE; MORNING DOSAGE; NAUSEA; NEUROCHEMISTRY; NIGHTMARE; NONHUMAN; OTALGIA; PANIC; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHARMACIST; PRIORITY JOURNAL; PROGNOSIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SOCIAL INTERACTION; SOMNOLENCE; SORE THROAT; SUICIDAL IDEATION; SYMPTOMATOLOGY; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA;

ADHD; AMPHETAMINE; ATOMOXETINE; ATTENTION-DEFICIT HYPERACTIVITY DISORDER; BUPROPION; CLONIDINE; DOPAMINE; ETIOLOGY; GUANFACINE; METHYLPHENIDATE; NOREPINEPHRINE; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; TREATMENT; TREATMENT GUIDELINES; TRICYCLIC ANTIDEPRESSANTS;

AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG INTERACTIONS; HUMANS; METHYLPHENIDATE; PROPYLAMINES;

EID: 84893319241     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013510699     Document Type: Review

References (131)

1. Berger I.Diagnosis of attention deficit hyperactivity disorder: much ado about something.Isr Med Assoc J. 2011;13:571-574.
2. Childress AC,Berry SA.Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents.Drugs. 2012;72:309-325.
3. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.Washington, DC: American Psychiatric Association; 2013.Washington, DC: American Psychiatric Association; 2013:.
4. Cortese S.The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know.Eur J Paediatr Neurol. 2012;16:422-433.
5. Dopheide JA.ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients.Am J Health Syst Pharm. 2005;62:1502-1509.
6. Maul J,Advokat C.Stimulant medications for attention-deficit/hyperactivity disorder (ADHD) improve memory of emotional stimuli in ADHD-diagnosed college students.Pharmacol Biochem Behav. 2013;105:58-62.
7. Modesto-Lowe V,Meyer A,Soovajian V.A clinician's guide to adult attention-deficit hyperactivity disorder.Conn Med. 2012;76:517-523.
8. Biederman J,Faraone SV,Spencer TJ,Mick E,Monuteaux MC,Aleardi M.Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community.J Clin Psychiatry. 2006;67:524-540.
9. Arnsten AF,Pliszka SR.Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.Pharmacol Biochem Behav. 2011;99:211-216.
10. Kesner RP,Churchwell JC.An analysis of rat prefrontal cortex in mediating executive function.Neurobiol Learn Mem. 2011;96:417-431.
11. Shaw P,Eckstrand K,Sharp W,et al.Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation.Proc Natl Acad Sci U S A. 2007;104:19649-19654.
12. Arnsten AF.Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness.Cereb Cortex. 2007;17:i6-i15.
13. Arnsten AF,Paspalas CD,Gamo NJ,Yang Y,Wang M.Dynamic network connectivity: a new form of neuroplasticity.Trends Cogn Sci. 2010;14:365-375.
14. Pliszka SR.The neuropsychopharmacology of attention-deficit/hyperactivity disorder.Biol Psychiatry. 2005;57:1385-1390.
15. Robbins TW.Dopamine and cognition.Curr Opin Neurol. 2003;16:S1-S2.
16. Bowton E,Saunders C,Erreger K,et al.Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder.J Neurosci. 2010;30:6048-6057.
17. Wang M,Ramos BP,Paspalas CD,et al.Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex.Cell. 2007;129:397-410.
18. Tripp G,Wickens JR.Neurobiology of ADHD.Neuropharmacology. 2009;57:579-589.
19. Fusar-Poli P,Rubia K,Rossi G,Sartori G,Balottin U.Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis.Am J Psychiatry. 2012;169:264-272.
20. Gizer IR,Ficks C,Waldman ID.Candidate gene studies of ADHD: a meta-analytic review.Hum Genet. 2009;126:51-90.
21. Mazei-Robison MS,Bowton E,Holy M,et al.Anomalous dopamine release associated with a human dopamine transporter coding variant.J Neurosci. 2008;28:7040-7046.
22. Sakrikar D,Mazei-Robison MS,Mergy MA,et al.Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation.J Neurosci. 2012;32:5385-5397.
23. Langer DH,Rapoport JL,Brown GL,Ebert MH,Bunney WE.Behavioral effects of carbidopa/levodopa in hyperactive boys.J Am Acad Child Psychiatry. 1982;21:10-18.
24. Overtoom CC,Verbaten MN,Kemner C,et al.Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with attention deficit hyperactivity disorder.Behav Brain Res. 2003;145:7-15.
25. Howells FM,Stein DJ,Russell VA.Synergistic tonic and phasic activity of the locus coeruleus norepinephrine (LC-NE) arousal system is required for optimal attentional performance.Metab Brain Dis. 2012;27:267-274.
26. Baumeister AA,Hawkins MF.Incoherence of neuroimaging studies of attention deficit/hyperactivity disorder.Clin Neuropharmacol. 2001;24:2-10.
27. Bush G.Neuroimaging of attention deficit hyperactivity disorder: can new imaging findings be integrated in clinical practice?.Child Adolesc Psychiatr Clin N Am. 2008;17:385-404.
28. Bush G,Valera EM,Seidman LJ.Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions.Biol Psychiatry. 2005;57:1273-1284.
29. Perlov E,Philipsen A,Matthies S,et al.Spectroscopic findings in attention-deficit/hyperactivity disorder: review and meta-analysis.World J Biol Psychiatry. 2009;10:355-365.
30. Durston S.Converging methods in studying attention-deficit/hyperactivity disorder: what can we learn from neuroimaging and genetics?.Dev Psychopathol. 2008;20:1133-1143.
31. Zimmer L.Positron emission tomography neuroimaging for a better understanding of the biology of ADHD.Neuropharmacology. 2009;57:601-607.
32. Kehoe WA.Treatment of attention deficit hyperactivity disorder in children.Ann Pharmacother. 2001;35:1130-1134.
33. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.Washington, DC: American Psychiatric Association; 2000:.
34. Trent S,Davies W.The influence of sex-linked genetic mechanisms on attention and impulsivity.Biol Psychol. 2012;89:1-13.
35. Rader R,McCauley L,Callen EC.Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.Am Fam Physician. 2009;79:657-665.
36. Collett BR,Ohan JL,Myers KM.Ten-year review of rating scales: V. Scales assessing attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2003;42:1015-1037.
37. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
38. Parker A,Corkum P.ADHD diagnosis: as simple as administering a questionnaire or a complex diagnostic process?.J Atten Disord.:.
39. Elia J,Ambrosini PJ,Rapoport JL.Treatment of attention-deficit-hyperactivity disorder.N Engl J Med. 1999;340:780-788.
40. Knouse LE,Cooper-Vince C,Sprich S,Safren SA.Recent developments in the psychosocial treatment of adult ADHD.Expert Rev Neurother. 2008;8:1537-1548.
41. Knouse LE,Safren SA.Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder.Psychiatr Clin North Am. 2010;33:497-509.
42. The MTA cooperative group: multimodal treatment study of children with ADHD.Arch Gen Psychiatry. 1999;56:1073-1086.
43. National Institute of Mental Health multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder.Pediatrics. 2004;113:754-761.
44. Jensen PS,Arnold LE,Swanson JM,et al.3-year follow-up of the NIMH MTA study.J Am Acad Child Adolesc Psychiatry. 2007;46:989-1002.
45. Molina BS,Hinshaw SP,Swanson JM,et al.The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.J Am Acad Child Adolesc Psychiatry. 2009;48:484-500.
46. Dopheide JA,Pliszka SR.Attention-deficit-hyperactivity disorder: an update.Pharmacotherapy. 2009;29:656-679.
47. Swanson J,Arnold LE,Kraemer H,et al.Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD (MTA): part I. Executive summary.J Atten Disord. 2008;12:4-14.
48. Swanson J,Arnold LE,Kraemer H,et al.Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD (MTA): part II. Supporting details.J Atten Disord. 2008;12:15-43.
49. Pelham WE,Burrows-Maclean L,Gnagy EM,et al.Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.Exp Clin Psychopharmacol. 2005;13:111-126.
50. Stevens JR,George RA,Fusillo S,Stern TA,Wilens TE.Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.J Child Adolesc Psychopharmacol. 2010;20:49-54.
51. Seiden LS,Sabol KE,Ricaurte GA.Amphetamine: effects on catecholamine systems and behavior.Annu Rev Pharmacol Toxicol. 1993;33:639-677.
52. Levi G,Raiteri M.Carrier-mediated release of neurotransmitters.Trends Neurosci. 1993;16:415-419.
53. Volkow ND,Ding YS,Fowler JS,et al.Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain.Arch Gen Psychiatry. 1995;52:456-463.
54. Pliszka SR.Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action.Neuropsychol Rev. 2007;17:61-72.
55. Spencer TJ,Abikoff HB,Connor DF,et al.Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.Clin Ther. 2006;28:402-418.
56. Wilens TE,McBurnett K,Bukstein O,et al.Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.Arch Pediatr Adolesc Med. 2006;160:82-90.
57. Faraone SV.Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.Expert Opin Pharmacother. 2008;9:1565-1574.
58. Biederman J,Boellner SW,Childress A,Lopez FA,Krishnan S,Zhang Y.Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.Biol Psychiatry. 2007;62:970-976.
59. Nutt D,King LA,Saulsbury W,Blakemore C.Development of a rational scale to assess the harm of drugs of potential misuse.Lancet. 2007;369:1047-1053.
60. Berridge CW,Devilbiss DM,Andrzejewski ME,et al.Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.Biol Psychiatry. 2006;60:1111-1120.
61. Biederman J,Wilens T,Mick E,Spencer T,Faraone SV.Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.Pediatrics. 1999;104:e20.
62. Biederman J.Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without ADHD.J Clin Psychiatry. 2003;64:3-8.
63. Mannuzza S,Klein RG,Truong NL,et al.Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.Am J Psychiatry. 2008;165:604-609.
64. Frodl T.Comorbidity of ADHD and substance use disorder (SUD): a neuroimaging perspective.J Atten Disord. 2010;14:109-120.
65. Biederman J,Monuteaux MC,Spencer T,Wilens TE,Faraone SV.Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study.Pediatrics. 2009;124:71-78.
66. Connor DF,Glatt SJ,Lopez ID,Jackson D,Melloni RH.Psychopharmacology and aggression: I. A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.J Am Acad Child Adolesc Psychiatry. 2002;41:253-261.
67. Upadhyaya HP,Rose K,Wang W,et al.Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults.J Child Adolesc Psychopharmacol. 2005;15:799-809.
68. Smith ME,Farah MJ.Are prescription stimulants "smart pills"? the epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals.Psychol Bull. 2011;137:717-741.
69. Advokat C.What exactly are the benefits of stimulants for ADHD?.J Atten Disord. 2009;12:495-498.
70. Advokat C.What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD).Neurosci Biobehav Rev. 2010;34:1256-1266.
71. Gamo NJ,Wang M,Arnsten AF.Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors.J Am Acad Child Adolesc Psychiatry. 2010;49:1011-1023.
72. Biederman J,Spencer TJ,Monuteaux MC,Faraone SV.A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.J Pediatr. 2010;157:635 640.e1-640.
73. J Am Acad Child Adolesc Psychiatry. 1997;36:85S-121S.
74. Poulton A.Growth on stimulant medication; clarifying the confusion. A review.Arch Dis Child. 2005;90:801-806.
75. Faraone SV,Biederman J,Monuteaux M,Spencer T.Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on growth.J Child Adolesc Psychopharmacol. 2005;15:191-202.
76. Faraone SV,Biederman J,Morley CP,Spencer TJ.Effect of stimulants on height and weight: a review of the literature.J Am Acad Child Adolesc Psychiatry. 2008;47:994-1009.
77. National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.Pediatrics. 2004;113:762-769.
78. Swanson J,Greenhill L,Wigal T,et al.Stimulant-related reductions of growth rates in the PATS.J Am Acad Child Adolesc Psychiatry. 2006;45:1304-1313.
79. Spencer TJ,Biederman J,Harding M,O'Donnell D,Faraone SV,Wilens TE.Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?.J Am Acad Child Adolesc Psychiatry. 1996;35:1460-1469.
80. Pliszka SR,Matthews TL,Braslow KJ,Watson MA.Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2006;45:520-526.
81. Shaw P,Sharp WS,Morrison M,et al.Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder.Am J Psychiatry. 2009;166:58-63.
82. Schnoebelen S,Semrud-Clikeman M,Pliszka SR.Corpus callosum anatomy in chronically treated and stimulant naive ADHD.J Atten Disord. 2010;14:256-266.
83. Nissen SE.ADHD drugs and cardiovascular risk.N Engl J Med. 2006;354:1445-1448.
84. Greenhill LL,Findling RL,Swanson JM.A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.Pediatrics. 2002;109:E39.
85. Greenhill LL,Muniz R,Ball RR,Levine A,Pestreich L,Jiang H.Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2006;45:817-823.
86. Findling RL,Turnbow J,Burnside J,Melmed R,Civil R,Li Y.A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents.CNS Spectr. 2010;15:419-430.
87. Shier AC,Reichenbacher T,Ghuman HS,Ghuman JK.Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies.J Cent Nerv Syst Dis. 2012;5:1-17.
88. Capp PK,Pearl PL,Conlon C.Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.Expert Rev Neurother. 2005;5:325-331.
89. Faraone SV,Buitelaar J.Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.Eur Child Adolesc Psychiatry. 2010;19:353-364.
90. Volkow ND,Wang GJ,Fowler JS,et al.Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.Am J Psychiatry. 1998;155:1325-1331.
91. Volkow ND,Wang GJ,Fowler JS,et al.Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain.Am J Psychiatry. 2004;161:1173-1180.
92. Zhang J,Deng Y,Fang J,McKay G.Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase.Pharm Res. 2003;20:1881-1884.
93. East Hanover, NJ: Novartis Pharmaceuticals; 2007:.
94. Vacaville, CA: Janssen-Cilag; 2010:.
95. Smyrna, GA: UCB Manufacturing; 2013:.
96. East Hanover, NJ: Novartis Pharmaceuticals; 2013:.
97. Miami, FL: Noven Pharmaceuticals; 2010:.
98. Stevenson RD,Wolraich ML.Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.Pediatr Clin North Am. 1989;36:1183-1197.
99. Greenfield B,Hechman L.Treatment of attention deficit hyperactivity disorder in adults.Expert Rev Neurother. 2005;5:107-121.
100. Swanson J,Gupta S,Guinta D,et al.Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.Clin Pharmacol Ther. 1999;66:295-305.
101. Swanson J,Gupta S,Lam A,et al.Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.Arch Gen Psychiatry. 2003;60:204-211.
102. Swanson JM,Volkow ND.Serum and brain concentrations of methylphenidate: Implications for use and abuse.Neurosci Biobehav Rev. 2003;27:615-621.
103. Anderson VR,Scott LJ.Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in children.Drugs. 2006;66:1117-1126.
104. North Wales, PA: Teva Pharmaceuticals; 2012:.
105. Chesterbrook, PA: Shire US; 2013:.
106. Advokat C.Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD.J Atten Disord. 2007;11:8-16.
107. Spencer T,Biederman J,Wilens T.Nonstimulant treatment of adult attention-deficit/hyperactivity disorder.Psychiatr Clin North Am. 2004;27:373-383.
108. Waxmonsky JG.Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.Essent Psychopharmacol. 2005;6:262-276.
109. Faraone SV.Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths.P T. 2009;34:678-694.
110. Faraone SV,Glatt SJ.A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.J Clin Psychiatry. 2010;71:754-763.
111. Hazell PL,Kohn MR,Dickson R,Walton RJ,Granger RE,Wyk GW.Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.J Atten Disord. 2011;15:674-683.
112. Greenhill LL,Pliszka S,Dulcan MK,et al.Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
113. Wernicke JF,Kratochvil CJ.Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.J Clin Psychiatry. 2002;63:50-55.
114. Bymaster FP,Katner JS,Nelson DL,et al.Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.Neuropsychopharmacology. 2002;27:699-711.
115. Chamberlain SR,Muller U,Blackwell AD,Clark L,Robbins TW,Sahakian BJ.Neurochemical modulation of response inhibition and probabilistic learning in humans.Science. 2006;311:861-863.
116. Chamberlain SR,Del Campo N,Dowson J,et al.Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.Biol Psychiatry. 2007;62:977-984.
117. Banaschewski T,Roessner V,Dittmann RW,Santosh PJ,Rothenberger A.Non-stimulant medications in the treatment of ADHD.Eur Child Adolesc Psychiatry. 2004;13:I102-I116.
118. Castellanos FX,Kelly C.Catecholamine modulators: lessons from nonhuman primates.J Am Acad Child Adolesc Psychiatry. 2010;49:977-979.
119. Rains A,Scahill L,Hamrin V.Nonstimulant medications for the treatment of ADHD.J Child Adolesc Psychiatr Nurs. 2006;19:44-47.
120. Indianapolis, IN: Eli Lilly; 2012:.
121. Chesterbrook, PA: Shire US; 2011:.
122. Florham Park, NJ: Shionogi; 2013:.
123. Pliszka SR.Non-stimulant treatment of attention-deficit/hyperactivity disorder.CNS Spectr. 2003;8:253-258.
124. Engberg G,Eriksson E.Effects of alpha 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats.Naunyn Schmiedebergs Arch Pharmacol. 1991;343:472-477.
125. Pliszka SR,Crismon ML,Hughes CW,et al.The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2006;45:642-657.
126. Daviss WB,Perel JM,Rudolph GR,et al.Steady-state pharmacokinetics of bupropion SR in juvenile patients.J Am Acad Child Adolesc Psychiatry. 2005;44:349-357.
127. Research Triangle Park, NC: GlaxoSmithKline; 2013:.
128. Browman KE,Curzon P,Pan JB,et al.A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats.Pharmacol Biochem Behav. 2005;82:148-155.
129. Woolley ML,Waters KA,Reavill C,et al.Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat.Behav Pharmacol. 2008;19:765-776.
130. Wilens TE,Biederman J,Spencer TJ,et al.A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder.Am J Psychiatry. 1999;156:1931-1937.
131. Wolraich M,Brown L,Brown RT,et al.ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.Pediatrics. 2011;128:1007-1022.